Early cancer diagnosis and prediction of responsivity to treatments are crucial elements for favorable prognosis and increased effectiveness of therapies in cancer patients. This special issue compiles relevant articles focused on the development of innovative cancer biomarkers and their validation.
Availability of advanced molecular biology tools, including deep-sequencing and RNA-seq, allowed the identification of new unique biomarkers for more sensitive and specific diagnosis and the possibility to select new candidate therapeutic targets for personalized medicine.
The negative prognostic role of stem cell markers, with higher progression rate, has been reported by G. Chene et al. Finally identification of HHV-8 sequences in conjunctival neoplasia of Uganda patients offers the possibility to unveil a further cancer association to such herpesvirus and highlights the need to look for indirect role of virus with low-modest oncogenic potential in immunodeficient patients (including low risk HPVs in HIV-positive patients).
By compiling these papers, we hope to enrich our readers and researchers with respect to the current wide range of cancer biomarkers, actively pursued by several worldwide research groups.
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